Publication | Open Access

390P Vepdegestrant, a proteolysis targeting chimera (PROTAC) estrogen receptor (ER) degrader, in ER+/human epidermal growth factor receptor 2 (HER2)- advanced breast cancer: Update of dose escalation results from a phase I/II trial

Endocrine OncologyBreast OncologyOncologyMedicineHormonal ReceptorEstrogen ReceptorBreast CancerPharmacotherapyPhase I/ii TrialCancer TreatmentPharmacologyRadiation OncologyDose Escalation ResultsEndocrine-related Cancer